← All stories
Markets
Why is Oxford Biomedica (LSE:OXB) splitting opinion this week between record client wins and a trimmed revenue outlook?
Highlights New client signings reached the busiest level the group has recorded Near-term revenue expectations were lowered on slower ordering and a delayed site ramp A commercial supply agreement with a major pharmaceutical partner underli…
Covered by 1 outlet
All coverage · 1 article